地塞米松治疗对比手术治疗慢性硬膜下血肿(DECSA试验):随机对照试验研究方案
DECSA试验为前瞻性多中心随机对照试验,纳入Markwalder分级1–3级的慢性硬膜下血肿患者,比较首选地塞米松治疗与首选钻孔开颅手术的功能结局和成本效果。地塞米松方案为每日16 mg起逐步减量至第20天停药,主要结局为3个月改良Rankin量表评分和12个月成本效果,计划每组210例、共420例,以非劣效性检验评估地塞米松是否不劣于手术。
要点
- 慢性硬膜下血肿手术复发率可高达30%,地塞米松被视为非手术替代但成功率可能较低。
- 地塞米松方案:每日16 mg(8 mg每日两次,第1–4天),每3天减半,第19天0.5 mg/日,第20天停药。
- 主要结局为3个月mRS功能结局和12个月成本效果,采用非劣效性设计,每组需210例。
核心结论
- 本研究旨在验证地塞米松治疗在功能结局上是否不劣于钻孔开颅手术,且成本更低。
研究设计与样本
- 前瞻性、多中心、随机对照试验,连续纳入Markwalder分级1–3级的慢性硬膜下血肿患者,随机分配至地塞米松组或钻孔开颅手术组。
- 计划每组210例、共420例,3年内以60%入组率完成,采用非劣效性检验(假定校正共同优势比1.15,劣效界值<0.9)。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 地塞米松方案:每日16 mg(8 mg每日两次,第1–4天),随后每3天减半,第19天0.5 mg/日,第20天停药。
- 若治疗反应不足(症状持续或进展且血肿吸收不充分),可追加手术。
- 主要结局为3个月改良Rankin量表评分和12个月成本效果;次要结局包括3和12个月SF-36与QOLIBRI生活质量、2周CT血肿厚度、12个月内复发、并发症与药物不良事件、治疗失败需干预、3和12个月死亡率、住院时长及总体医疗与生产力成本。
临床怎么用
- 为临床医生在症状性慢性硬膜下血肿患者中选择地塞米松或手术提供头对头随机对照证据。
局限性
- 本文为研究方案,尚无结果数据,结论待试验完成后确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic subdural haematoma (CSDH) is a common neurological disease with a rapidly rising incidence due to increasing age and widespread use of anticoagulants. Surgical intervention by burr-hole craniotomy (BHC) is the current standard practice for symptomatic patients, but associated with complications, a recurrence rate of up to 30% and increased mortality. Dexamethasone (DXM) therapy is, therefore, used as a non-surgical alternative but considered to achieve a lower success rate. Furthermore, the benefit of DXM therapy appears much more deliberate than the immediate relief from BHC. Lack of evidence and clinical equipoise among caregivers prompts the need for a head-to-head randomised controlled trial. The objective of this study is to compare the effect of primary DXM therapy versus primary BHC on functional outcome and cost-effectiveness in symptomatic patients with CSDH. METHODS/DESIGN: This study is a prospective, multicentre, randomised controlled trial (RCT). Consecutive patients with a CSDH with a Markwalder Grading Scale (MGS) grade 1 to 3 will be randomised to treatment with DXM or BHC. The DXM treatment scheme will be 16 mg DXM per day (8 mg twice daily, days 1 to 4) which is then halved every 3 days until a dosage of 0.5 mg a day on day 19 and stopped on day 20. If the treatment response is insufficient (i.e. persistent or progressive symptomatology due to insufficient haematoma resolution), additional surgery can be performed. The primary outcomes are the functional outcome by means of the modified Rankin Scale (mRS) score at 3 months and cost-effectiveness at 12 months. Secondary outcomes are quality of life at 3 and 12 months using the Short Form Health Survey (SF-36) and Quality of Life after Brain Injury Overall Scale (QOLIBRI), haematoma thickness after 2 weeks on follow-up computed tomography (CT), haematoma recurrence during the first 12 months, complications and drug-related adverse events, failure of therapy within 12 months after randomisation and requiring intervention, mortality during the first 3 and 12 months, duration of hospital stay and overall healthcare and productivity costs. To test non-inferiority of DXM therapy compared to BHC, 210 patients in each treatment arm are required (assumed adjusted common odds ratio DXM compared to BHC 1.15, limit for inferiority < 0.9). The aim is to include a total of 420 patients in 3 years with an enrolment rate of 60%. DISCUSSION: The present study should demonstrate whether treatment with DXM is as effective as BHC on functional outcome, at lower costs. TRIAL REGISTRATION: EUCTR 2015-001563-39 . Date of registration: 29 March 2015.
引用
- Miah IP, Holl DC, Peul WC, et al. Dexamethasone therapy versus surgery for chronic subdural haematoma (DECSA trial): study protocol for a randomised controlled trial. Trials. 2018. PMID: 30342554. doi:10.1186/s13063-018-2945-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。